{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:01:18Z","timestamp":1792450878776,"version":"4.5.0"},"reference-count":148,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MRF-169-0001-F-STAM-C0826, MIBTP Studentship"],"award-info":[{"award-number":["MRF-169-0001-F-STAM-C0826, MIBTP Studentship"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010757","name":"National Centre for the Replacement Refinement and Reduction of Animals in Research","doi-asserted-by":"publisher","award":["Trainee Fellowship"],"award-info":[{"award-number":["Trainee Fellowship"]}],"id":[{"id":"10.13039\/501100010757","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Persistent liver inflammation can lead to cirrhosis, which associates with significant morbidity and mortality worldwide. There are no curative treatments beyond transplantation, followed by long-term immunosuppression. The global burden of end stage liver disease has been increasing and there is a shortage of donor organs, therefore new therapies are desperately needed. Harnessing the power of the immune system has shown promise in certain autoimmunity and cancer settings. In the context of the liver, regulatory T cell (Treg) therapies are in development. The hypothesis is that these specialized lymphocytes that dampen inflammation may reduce liver injury in patients with chronic, progressive diseases, and promote transplant tolerance. Various strategies including intrinsic and extracorporeal expansion of Treg cells, aim to increase their abundance to suppress immune responses. We recently discovered that hepatocytes engulf and delete Treg cells by enclysis. Herein, we propose that inhibition of enclysis may potentiate existing regulatory T cell therapeutic approaches in patients with autoimmune liver diseases and in patients receiving a transplant. Moreover, in settings where the abundance of Treg cells could hinder beneficial immunity, such us in chronic viral infection or liver cancer, enhancement of enclysis could result in transient, localized reduction of Treg cell numbers and tip the balance towards antiviral and anti-tumor immunity. We describe enclysis as is a natural process of liver immune regulation that lends itself to therapeutic targeting, particularly in combination with current Treg cell approaches.<\/jats:p>","DOI":"10.3389\/fimmu.2021.662134","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T04:12:47Z","timestamp":1618805567000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Yara O.","family":"Aghabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Yasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber E.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zania","family":"Stamataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"B1","unstructured":"Liver Disease Crisis, British Liver Trust2019"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32866-0","article-title":"Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK","volume":"391","author":"Williams","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol"},{"key":"B4","volume-title":"Hepatitis B","year":"2020"},{"key":"B5","volume-title":"Hepatitis C","year":"2020"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"20","author":"Krassenburg","year":"2020","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4254\/wjh.v10.i1.1","article-title":"Role of inflammatory response in liver diseases: Therapeutic strategies","volume":"10","author":"Del Campo","year":"2018","journal-title":"World J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01586","article-title":"Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases","volume":"11","author":"Richardson","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052415","article-title":"Immune Responses in the Liver","volume":"36","author":"Kubes","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau2688","article-title":"Treg cells-the next frontier of cell therapy","volume":"362","author":"Bluestone","year":"2018","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00043","article-title":"Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity","volume":"10","author":"Romano","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.015","article-title":"Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier","volume":"142","author":"Esensten","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00334","article-title":"Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives","volume":"7","author":"Jeffery","year":"2016","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cdtm.2016.09.001","article-title":"Regulatory T-cells promote hepatitis B virus infection and hepatocellular carcinoma progression","volume":"2","author":"Li","year":"2016","journal-title":"Chronic Dis Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2018.10.005","article-title":"Early high levels of regulatory T cells and T helper 1 may predict the progression of recurrent hepatitis C after liver transplantation","volume":"43","author":"Ghazal","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.coi.2019.03.007","article-title":"NextGen cell-based immunotherapies in cancer and other immune disorders","volume":"59","author":"Azimi","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.09.068","article-title":"Hepatocytes delete regulatory T cells by enclysis, a CD4+ T cell engulfment process","volume":"29","author":"Davies","year":"2019","journal-title":"Cell Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00650","article-title":"Cell-in-Cell Structures in the Liver: A Tale of Four E\u2019s","volume":"11","author":"Davies","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00044","article-title":"Clearance of Apoptotic Cells by Tissue Epithelia: A Putative Role for Hepatocytes in Liver Efferocytosis","volume":"9","author":"Davies","year":"2018","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1112251108","article-title":"Hepatocyte entry leads to degradation of autoreactive CD8 T cells","volume":"108","author":"Benseler","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/nrm2504","article-title":"The cell biology of cell-in-cell structures","volume":"9","author":"Overholtzer","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.10.040","article-title":"A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion","volume":"131","author":"Overholtzer","year":"2007","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","article-title":"Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities","volume":"55","author":"Vesterhus","year":"2020","journal-title":"J Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.05.041","article-title":"Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets","volume":"73","author":"Carbone","year":"2020","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00117","article-title":"New Therapeutic Targets in Autoimmune Cholangiopathies","volume":"7","author":"Gerussi","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043534","article-title":"Cellular and Molecular Mechanisms of Autoimmune Hepatitis","volume":"13","author":"Webb","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.12940","article-title":"Low-dose interleukin-2 promotes STAT-5 phosphorylation, T(reg) survival and CTLA-4-dependent function in autoimmune liver diseases","volume":"188","author":"Jeffery","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.11.006","article-title":"Grand round: Autoimmune hepatitis","volume":"70","author":"Trivedi","year":"2019","journal-title":"J Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/cei.12956","article-title":"Immunosuppressive drugs affect interferon (IFN)-\u03b3 and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis","volume":"189","author":"Grant","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62163-1","article-title":"Autoimmune hepatitis","volume":"382","author":"Heneghan","year":"2013","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/cld.296","article-title":"Update on Autoimmune Hepatitis","volume":"3","author":"Liberal","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.05.011","article-title":"Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies","volume":"69","author":"Pimpin","year":"2018","journal-title":"J Hepatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis","volume":"354","author":"Krawitt","year":"2006","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld","year":"2005","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27983","article-title":"Prediction of short- and long-term outcome in patients with autoimmune hepatitis","volume":"62","author":"Kirstein","year":"2015","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.10.005","article-title":"Liver antigen-presenting cells","volume":"54","author":"Crispe","year":"2011","journal-title":"J Hepatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.01.005","article-title":"T cell immunity in autoimmune hepatitis","volume":"4","author":"Ichiki","year":"2005","journal-title":"Autoimmun Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jaut.2009.08.010","article-title":"Aetiopathogenesis of autoimmune hepatitis","volume":"34","author":"Longhi","year":"2010","journal-title":"J Autoimmun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14062","article-title":"Autoimmune hepatitis: Current and future therapeutic options","volume":"39","author":"Doycheva","year":"2019","journal-title":"Liver Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MOG.0000000000000701","article-title":"Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation","volume":"37","author":"Weiler-Normann","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.565518","article-title":"The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations","volume":"11","author":"Terry","year":"2020","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26023","article-title":"Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance","volume":"57","author":"Lapierre","year":"2013","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26583","article-title":"Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis","volume":"59","author":"Grant","year":"2014","journal-title":"Hepatology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575572","article-title":"Regulatory T Cells in Autoimmune Hepatitis: Unveiling Their Roles in Mouse Models and Patients","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.7.4484","article-title":"Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis","volume":"176","author":"Longhi","year":"2006","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27884","article-title":"In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression","volume":"62","author":"Liberal","year":"2015","journal-title":"Hepatology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/hep.23792","article-title":"A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis","volume":"52","author":"Ferri","year":"2010","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","article-title":"Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis","volume":"25","author":"Longhi","year":"2005","journal-title":"J Autoimmun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.03.008","article-title":"Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease","volume":"41","author":"Longhi","year":"2004","journal-title":"J Hepatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25682","article-title":"The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9\/tim-3 pathway","volume":"56","author":"Liberal","year":"2012","journal-title":"Hepatology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/j.1872-034X.2008.00349.x","article-title":"Deficiency of forkhead box P3 and cytotoxic T-lymphocyte-associated antigen-4 gene expressions and impaired suppressor function of CD4(+)CD25(+) T cells in patients with autoimmune hepatitis","volume":"38","author":"Okumura","year":"2008","journal-title":"Hepatol Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2020.06.044","article-title":"Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis","volume":"74","author":"Vuerich","year":"2021","journal-title":"J Hepatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1038\/s41419-017-0010-y","article-title":"Increased apoptosis of regulatory T cells in patients with active autoimmune hepatitis","volume":"8","author":"John","year":"2017","journal-title":"Cell Death Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.029","article-title":"FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency","volume":"57","author":"Peiseler","year":"2012","journal-title":"J Hepatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30059","article-title":"Low-Dose Interleukin-2 for Refractory Autoimmune Hepatitis","volume":"68","author":"Lim","year":"2018","journal-title":"Hepatology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis 78"},{"key":"B59","doi-asserted-by":"publisher","first-page":"102591","DOI":"10.1016\/j.jaut.2020.102591","article-title":"Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis","volume":"117","author":"Buitrago-Molina","year":"2021","journal-title":"J Autoimmun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bbrc.2019.02.147","article-title":"Adoptive transfer of regulatory T cells stimulated by Allogeneic Hepatic Stellate Cells mitigates liver injury in mice with concanavalin A-induced autoimmune hepatitis","volume":"512","author":"Huang","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.clim.2018.11.003","article-title":"Treg\/Th17 imbalance is associated with poor autoimmune hepatitis prognosis","volume":"198","author":"Liu","year":"2019","journal-title":"Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jaut.2014.02.001","article-title":"Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2","volume":"53","author":"Holder","year":"2014","journal-title":"J Autoimmun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29307","article-title":"D. Vergani, and","volume":"66","author":"Liberal","year":"2017","journal-title":"Hepatology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12433","article-title":"Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation","volume":"13","author":"Putnam","year":"2013","journal-title":"Am J Transplant"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.08.001","article-title":"Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis","volume":"1","author":"Oo","year":"2019","journal-title":"JHEP Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.034","article-title":"Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies","volume":"61","author":"Taubert","year":"2014","journal-title":"J Hepatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/jmcb\/mjr047","article-title":"CD4(+)Foxp3(+) regulatory T cell therapy in transplantation","volume":"4","author":"Tang","year":"2012","journal-title":"J Mol Cell Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15700","article-title":"Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation","volume":"20","author":"Sanchez-Fueyo","year":"2020","journal-title":"Am J Transplant"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.05.034","article-title":"Regulatory T-cell directed therapies in liver diseases","volume":"59","author":"Oo","year":"2013","journal-title":"J Hepatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0334-4","article-title":"Understanding, predicting and achieving liver transplant tolerance: from bench to bedside","volume":"17","author":"Thomson","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28459","article-title":"A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12998","article-title":"Regulatory T-cell therapy in liver transplantation","volume":"30","author":"Whitehouse","year":"2017","journal-title":"Transpl Int"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90598","article-title":"Transplant trials with Tregs: perils and promises","volume":"127","author":"Tang","year":"2017","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T Cells and Human Disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/eji.201948131","article-title":"Treg cell therapy: How cell heterogeneity can make the difference","volume":"51","author":"Giganti","year":"2020","journal-title":"Eur J Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e01099","DOI":"10.1002\/cti2.1099","article-title":"Regulatory T cells in solid organ transplantation","volume":"9","author":"Atif","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/imr.12801","article-title":"The emerging role of regulatory T cells following lung transplantation","volume":"292","author":"Gauthier","year":"2019","journal-title":"Immunol Rev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"104220","DOI":"10.1016\/j.cellimm.2020.104220","article-title":"Building a CAR-Treg: Going from the basic to the luxury model","volume":"358","author":"Rosado-Sanchez","year":"2020","journal-title":"Cell Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2017.06.009","article-title":"Antigen-specific regulatory T cells: are police CARs the answer","volume":"187","author":"Dawson","year":"2017","journal-title":"Transl Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2017.0096","article-title":"Immunosuppression Practices in Liver Transplantation: A Survey of North American Centers","volume":"16","author":"Hussaini","year":"2018","journal-title":"Exp Clin Transplant"},{"key":"B82","doi-asserted-by":"publisher","first-page":"83ra42","DOI":"10.1126\/scitranslmed.3002076","article-title":"Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells","volume":"3","author":"Sagoo","year":"2011","journal-title":"Sci Transl Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J Autoimmun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01313","article-title":"Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes","volume":"8","author":"Yeh","year":"2017","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e11726","DOI":"10.1371\/journal.pone.0011726","article-title":"Human antigen-specific regulatory T cells generated by T cell receptor gene transfer","volume":"5","author":"Brusko","year":"2010","journal-title":"PloS One"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14185","article-title":"Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15787","article-title":"Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients","volume":"20","author":"Sicard","year":"2020","journal-title":"Am J Transplant"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4110\/in.2016.16.6.330","article-title":"Regulatory T Cells in Hepatitis B and C Virus Infections","volume":"16","author":"Jung","year":"2016","journal-title":"Immune Netw"},{"key":"B91","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31018-2","article-title":"The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts","volume":"388","author":"Wiktor","year":"2016","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030239","article-title":"Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection","volume":"197","author":"Shoukry","year":"2003","journal-title":"J Exp Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.12.022","article-title":"Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans","volume":"45","author":"Sprengers","year":"2006","journal-title":"J Hepatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.21.13239-13249.2005","article-title":"Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution","volume":"79","author":"Allen","year":"2005","journal-title":"J Virol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1015148108","article-title":"Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points","volume":"108","author":"Dietze","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.739","article-title":"Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B","volume":"177","author":"Xu","year":"2006","journal-title":"J Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.12.7852-7859.2005","article-title":"Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection","volume":"79","author":"Rushbrook","year":"2005","journal-title":"J Virol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.12.7860-7867.2005","article-title":"T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection","volume":"79","author":"Boettler","year":"2005","journal-title":"J Virol 79"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20454","article-title":"An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection","volume":"40","author":"Cabrera","year":"2004","journal-title":"Hepatology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.hep.2003.09.026","article-title":"Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection","volume":"38","author":"Sugimoto","year":"2003","journal-title":"Hepatology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3903","article-title":"Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C","volume":"107","author":"Manigold","year":"2006","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2598","article-title":"CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis","volume":"103","author":"Boyer","year":"2004","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl130","article-title":"Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B","volume":"19","author":"Yang","year":"2007","journal-title":"Int Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1086\/339340","article-title":"CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons","volume":"185","author":"MacDonald","year":"2002","journal-title":"J Infect Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"806061","DOI":"10.1155\/2011\/806061","article-title":"Hepatitis C virus induces regulatory T cells by naturally occurring viral variants to suppress T cell responses","volume":"2011","author":"Cusick","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"242ra81","DOI":"10.1126\/scitranslmed.3008793","article-title":"HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans","volume":"6","author":"Bohne","year":"2014","journal-title":"Sci Transl Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25765","article-title":"Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice","volume":"56","author":"Stross","year":"2012","journal-title":"Hepatology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10020221","article-title":"Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection","volume":"10","author":"Sung","year":"2021","journal-title":"J Clin Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-0351-y","article-title":"Regional immunity in tissue homeostasis and diseases","volume":"59","author":"Tian","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B117","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-052016-100322","article-title":"The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer","volume":"12","author":"Affo","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0074","article-title":"Diagnostic delays are common among patients with hepatocellular carcinoma","volume":"13","author":"Patel","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob Health"},{"key":"B121","doi-asserted-by":"publisher","first-page":"72","DOI":"10.21037\/tgh.2019.09.01","article-title":"Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies","volume":"4","author":"Pocha","year":"2019","journal-title":"Transl Gastroenterol Hepatol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i39.4436","article-title":"Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer","volume":"24","author":"O\u2019Rourke","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318224d669","article-title":"Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States","volume":"46","author":"Davila","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/cld.782","article-title":"Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future","volume":"13","author":"Likhitsup","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1998","article-title":"Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment","volume":"8","author":"Tarao","year":"2019","journal-title":"Cancer Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1159\/000343852","article-title":"From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence","volume":"2","author":"Ramakrishna","year":"2013","journal-title":"Liver Cancer"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i7.968","article-title":"Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful","volume":"7","author":"Takaki","year":"2015","journal-title":"World J Hepatol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1249-9","article-title":"Immune-based therapies for hepatocellular carcinoma","volume":"39","author":"Pinato","year":"2020","journal-title":"Oncogene"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2011.01437.x","article-title":"Regulatory T cell: a protection for tumour cells","volume":"16","author":"Wang","year":"2012","journal-title":"J Cell Mol Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B131","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ccr.2006.06.016","article-title":"Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment","volume":"10","author":"Budhu","year":"2006","journal-title":"Cancer Cell"},{"key":"B132","doi-asserted-by":"publisher","first-page":"e0231003","DOI":"10.1371\/journal.pone.0231003","article-title":"Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival","volume":"15","author":"Yu","year":"2020","journal-title":"PloS One"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.7150\/jca.21030","article-title":"Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis","volume":"8","author":"Zhou","year":"2017","journal-title":"J Cancer"},{"key":"B134","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000314","article-title":"FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor","volume":"47","author":"Leslie","year":"2015","journal-title":"Pathology"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29904","article-title":"Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification","volume":"68","author":"Kurebayashi","year":"2018","journal-title":"Hepatology"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e24679","DOI":"10.4161\/onci.24679","article-title":"High immunosuppressive burden in advanced hepatocellular carcinoma patients: Can effector functions be restored","volume":"2","author":"Lugade","year":"2013","journal-title":"Oncoimmunology"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12739","article-title":"CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway","volume":"151","author":"Penaloza-MacMaster","year":"2017","journal-title":"Immunology"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02427-4","article-title":"Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma","volume":"68","author":"Langhans","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"TPS4147","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS4147","article-title":"A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459","volume":"34","author":"Sangro","year":"2016","journal-title":"J Clin Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130116","article-title":"Augmentation of IFN-gamma+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy","volume":"4","author":"Kalathil","year":"2019","journal-title":"JCI Insight"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.05.003","article-title":"Treg-mediated acquired resistance to immune checkpoint inhibitors","volume":"457","author":"Saleh","year":"2019","journal-title":"Cancer Lett"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701155","article-title":"Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy","volume":"200","author":"Srivastava","year":"2018","journal-title":"J Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02293","article-title":"WNT\/beta-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau8694","article-title":"Immunity as a continuum of archetypes","volume":"364","author":"Mujal","year":"2019","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.662134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T04:12:54Z","timestamp":1618805574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.662134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":148,"alternative-id":["10.3389\/fimmu.2021.662134"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.662134","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"article-number":"662134"}}